Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service skin substitutes & wound grafts cases in Michigan: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (246 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 28 | 7,050 | 45% |
| 2020 | 20 | 6,005 | 51% |
| 2021 | 18 | 6,704 | 55% |
| 2022 | 18 | 7,877 | 59% |
| 2023 | 30 | 8,692 | 63% |
| 2024 | 37 | 10,345 | 66% |
| 2025 from claims | – | 9,608 8,818–10,166 | 67% |
| 2026 forecast | – | 10,313 9,074–11,901 | 67% |
| 2027 forecast | – | 11,008 9,411–13,118 | 68% |
| 2028 forecast | – | 11,744 9,800–14,381 | 69% |
| 2029 forecast | – | 12,524 10,229–15,707 | 70% |
| 2030 forecast | – | 13,349 10,695–17,107 | 70% |
Application of cellular and tissue-based products to wounds; the loudest category in Open Payments. Professional codes (what the surgeon bills): CPT 15271, 15273, 15275, 15277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 50% of the cases CMS names in Michigan; 22 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 0% inpatient hospital, 53% hospital outpatient, 46% office. The share outside the hospital has moved +29 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Office |
|---|---|---|
| 2026 · ~10,300 | ~5,500 | ~4,800 |
| 2027 · ~11,000 | ~5,900 | ~5,100 |
| 2028 · ~11,700 | ~6,300 | ~5,400 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 83 | 23,783+12%/yr | +12%/yr | 11.5 | 50% | 36,600 in 2030+7.5%/yr |
| Ohio | 39 | 12,139+7.6%/yr | +7.6%/yr | 6.3 | 47% | 15,800 in 2030+4.5%/yr |
| Indiana | 43 | 11,035+8.2%/yr | +8.2%/yr | 9.8 | 38% | 11,900 in 2030+1.2%/yr |
| Kansas | 36 | 8,726+10%/yr | +10%/yr | 16.1 | 71% | 13,300 in 2030+7.2%/yr |
| Missouri | 32 | 8,053+4.4%/yr | +4.4%/yr | 7.7 | 47% | 8,660 in 2030+1.2%/yr |
| Minnesota | 15 | 3,990+14%/yr | +14%/yr | 4.8 | 50% | 5,210 in 2030+4.5%/yr |
| Wisconsin | 12 | 3,903−0.1%/yr | −0.1%/yr | 3.9 | 25% | 4,360 in 2030+1.8%/yr |
| Iowa | 5 | 3,495−1.6%/yr | −1.6%/yr | 5.7 | 40% | 2,680 in 2030−4.3%/yr |
| Nebraska | 10 | 2,307+4.5%/yr | +4.5%/yr | 6.6 | 54% | 3,570 in 2030+7.5%/yr |
| South Dakota | 7 | 1,064−2.8%/yr | −2.8%/yr | 6.0 | 16% | 1,440 in 2030+5.1%/yr |
| North Dakota | 1 | 700+2.6%/yr | +2.6%/yr | 5.2 | 34% | 600 in 2030−2.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 430 | 65,322−6%/yr | −6%/yr | 73.00.9× | 40% | 65,100 in 20300%/yr |
| Bone graft & orthobiologics | 27 | 796−14%/yr | −14%/yr | 0.91.5× | 3% | 740 in 2030−1.1%/yr |
Skin substitutes & wound grafts in every state, and its device makers · Every procedure market in Michigan · Every state · Compare with Illinois
Kerecis leads with 39% of company spending on these surgeons in 2025, +9 pts on 2024.
In 2025, 30 companies reported engagement with Michigan’s surgeons worth $519K in consulting, speaking, meals and travel tied to these products, about $14K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 13 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.